Long-term metformin treatment was associated with fewer cardiovascular events than glipizide therapy in type 2 diabetes patients with a history of coronary artery disease, according to a study in Diabetes Care. Data on 304 patients showed 35.1% of glipizide-treated patients experienced cardiovascular events at five years, compared with 25% of metformin-treated patients.
Metformin outperforms glipizide in preventing CVD events in diabetes
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan